AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
ZANAMIVIR
4 registrations across 4 African markets— 3 active
Markets with ZANAMIVIR
🇲🇦Morocco
1 registration
1 active
🇲🇼Malawi
1 registration
0 active
🌍WW
1 registration
1 active
🇿🇦South Africa
1 registration
1 active
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| RELENZA 5MG /INHALER (20%W/W) INHALER INHALER | 🇲🇼Malawi | — | expired | Mar 2025 |
| RELENZA | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| RELENZA POUDRE POUR INHALATION | 🇲🇦Morocco | — | active | — |
| Zanamivir Powder, for Inhalation 5mg Powder, for Inhalation | 🌍WW | Glaxo Wellcome UK Ltd | active | — |
ZANAMIVIR in Africa — Regulatory Overview
ZANAMIVIR is registered across 4 African markets with 4 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Morocco, Malawi, WW, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 4 registrations, 3 (75%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.